Obesity Treatment Access
6 articles on Obesity Treatment Access, written by Shotlee and medically reviewed for clinical accuracy.
EU Approves Easier Wegovy Delivery, Easing Cold Chain Rules
Novo Nordisk has won EU regulatory approval to ease cold chain requirements for Wegovy injections, marking the first GLP-1 therapy in Europe with such delivery flexibility. The change allows a 48-hour window without refrigeration from pharmacies to patients, streamlining distribution and enhancing access. This aligns with trends in direct-to-patient models and complements recent subscription programs for better affordability.
5 min read
Novo Nordisk Expands Ozempic, Wegovy Testing on Adolescents
Novo Nordisk, maker of Ozempic and Wegovy, has launched a three-year research partnership to test weight-loss GLP-1 drugs on adolescents in Pacific Island nations, beginning in Fiji. Announced amid a Danish royal visit, this move addresses the obesity 'ticking bomb' threatening kids' lifespans. CEO Mike Doustdar urges bolder action on prevention and access.
5 min read
Mounjaro Shortage Harms Patients Amid Diet Craze: Supply Crisis
A surge in dieting demand has triggered shortages of Mounjaro's 5mg starting dose, making it hard for metabolic disease patients to access treatment. Clinics in Seoul report instability until late March, as non-reimbursed status leaves supply unmanaged. Patients like Mr. A face halted therapy despite proven benefits for diabetes control and weight loss.
6 min read
Mass. Patients Lose GLP-1 Coverage: $500/Month or Weight Regain Fear
After losing insurance coverage for GLP-1 drugs like Zepbound, Massachusetts patients are grappling with $500 monthly costs or the fear of regaining lost weight. Stories from Tierno, Markert, and others highlight the struggle, as doctors warn of health risks from discontinuation. Discover the coverage changes, patient impacts, and potential paths forward.
5 min read
Lilly Stockpiles $1.5B Orforglipron Ahead of FDA Approval Signal
Eli Lilly is sending a clear signal of confidence in its upcoming GLP-1 obesity pill, orforglipron, by stockpiling $1.5 billion worth of inventory ahead of FDA approval. This move, up from $550 million last year, anticipates robust demand without the supply chain issues that plagued injectables like Wegovy from 2022-2024. Here's what it means for patients seeking oral weight loss options.
5 min read
Weight-Loss Price Wars Upend Big Pharma's Model
Two years ago, GLP-1 prescriptions cost over $1,000 monthly for uninsured patients. Now, Wegovy's pill starts at $149, flipping Big Pharma's playbook amid fierce price wars. As Novo Nordisk forecasts sales drops and Eli Lilly surges, discover how consumer demand is reshaping obesity treatments.
6 min read